Clovis Lung Cancer Drug Needs More Study, FDA Panel Says

  • Panel votes 12-1 rociletinib needs study before FDA decision
  • Clinical trial will be complete in second half of 2018

Clovis Oncology Inc. should complete another clinical trial on its experimental drug for a form of lung cancer before U.S. regulators decide whether to approve it, a government advisory panel said Tuesday.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.